Genomic Analysis of Thyroid Carcinoma

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 207

Special Issue Editor


E-Mail Website
Guest Editor
Department of Surgery, Konkuk University Medical Centre, Konkuk University School of Medicine, 120 Neungdong-ro, Gwangjin-gu, Seoul 143-729, Republic of Korea
Interests: breast cancer; thyroid cancer; endocrine neoplasm; parathyroid gland; adrenal tumour
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

During the past several decades, the incidence rate of thyroid diseases has increased year by year and has reached an epidemic level. Previous studies have shown that the occurrence and development of thyroid cancer are affected by many factors, including oncogene mutation, methylation, and copy number increase. Recent studies have also shown that the progression of thyroid cancer is closely related to gene mutations. Thyroid cancer gene mutation is a major cause of thyroid cancer progression, and it is closely related to thyroid cancer diagnosis, prognosis evaluation, surgical planning, and targeted drug therapy. The treatment guidelines for patients with thyroid cancer point out that targeted therapy based on genomic status can effectively prolong the progression-free survival of patients with thyroid cancer, without affecting the quality of life of the patients. The genes of BRAF, TERT, p53, RET, and RAS related to thyroid cancer have been found in succession. However, the clinical significance of those genetic changes in thyroid cancer is still uncertain. Therefore, a more in-depth understanding of the various genetic changes in thyroid patients is crucial for elucidating the pathogenesis and formulating accurate targeted treatment plans.

Dr. Kyoung Sik Park
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • thyroid carcinoma
  • thyroid
  • BRAF
  • TERT
  • p53
  • RET
  • RAS

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop